Abstract
Myelosuppression is one of the major side effects of most anticancer drugs. To confer myeloprotection, our laboratory generated drug-resistant mutants of select target human enzymes for gene transfer to the bone marrow. Mutants of two of these enzymes, dihydrofolate reductase (DHFR F/S) and thymidylate synthase (TS G52S), were previously shown to confer resistance to methotrexate and 5-FU, respectively, and recently a fusion cDNA of both mutant enzymes (DHFR F/S-TS G52S) was shown to confer dual resistance to both antimetabolites. In this study, we examined the sensitivity of the DHFR F/S-TS G52S fusion protein to the multitargeted antifolate, pemetrexed (LY231514, Alimta), which targets both DHFR and TS and is currently in phase III trials for the treatment of solid tumors and in combination with cisplatin has been shown to be an advance in the treatment of mesothelioma. The Ki for the DHFR F/S portion of the purified fusion protein to pemetrexed was increased by greater than 9000-fold when compared to wtDHFR (8000 versus 0.86 nM), while the Ki for the TS G52S portion of the fusion protein to pemetrexed was similar to that of wtTS (2.8 versus 3.1 nM). When the fusion gene was retrovirally transduced into NIH 3T3 fibroblasts, the IC50 to pemetrexed was three- to four-fold higher than cells transduced with DHFR F/S or TS G52S alone (163 versus 53 and 45 nM, respectively). Similarly, expression of the DHFR F/S–TS G52S fusion gene in retrovirally transduced mouse marrow cells resulted in an increased survival of CFU-GM colonies when compared to cells transduced with either of the mutants alone. Co-expression of mutant DHFR and TS enzymes has additive effects in conferring resistance to pemetrexed-induced toxicity. This construct may be useful for conferring myeloprotection to patients receiving this drug.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Capiaux GM, Budak-Alpdogan T, Takebe N, et al. Retroviral transduction of a mutant dihydrofolate reductase thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Human Gene Ther. 2003;14:435–446.
Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116–1123.
Curtin NJ, Hughes AN . Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol. 2001;2:298–306.
Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res. 2000;6:1016–1023.
Banerjee D, Bertino JR . Myeloprotection with drug resistance genes. Lancet Oncol. 2002;3:154–158.
Bonadonna G, Zambetti M, Valagussa P . Sequential or alternating Doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes. 10 year results. JAMA. 1995;273:542–547.
Bertino JR . Biomodulation of 5-fluorouracil with antifolates. Semin Oncol. 1997;24:S18-52–S18-56.
Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol. 1989;7:1437–1446.
de Mulder PH . The chemotherapy of head and neck cancer. Anticancer Drugs. 1999;10:S33–S37.
Markowitz D, Goff S, Band A . Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 1988;167:400–406.
Hillcoat BL, Nixon PF, Blakley RL . Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase. Anal Biochem. 1967;21:179–189.
Ellis KJ, Morrison JF . Buffers of constant ionic strength for studying pH dependent processes. Methods Enzymol. 1982;87:405–426.
Wahba AJ, Friedkin M . Direct spectophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate. J Biol Chem. 1961;236:11–12.
Ercikan-Abali EA, Waltham MC, Dicker AP, et al. Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties. Mol Pharmacol. 1996;49:430–437.
Tong Y, Liu-Chen X, Ercikan-Abali EA, Capiaux GM, Banerjee D, Bertino JR . Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J Biol Chem. 1998a;273:11611–11618.
Williams JW, Morrison JF . The kinetics of reversible tight binding inhibition. Methods Enzymol. 1979;63:437–467.
Williams JW, Morrison JF, Duggleby RG . Methotrexate, a high affinity pseudosubstrate of dihydrofolate reductase. Biochemistry. 1979;18:2567–2573.
Duggleby RG . Regression analysis of nonlinear Arrhenius plots: an empirical model and a computer program. Comput Biol Med. 1984;14:447–455.
Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998;4:1136–1143.
Ercikan-Abali EA, Mineishi S, et al. Active site-directed double mutants of dihydrofolate reductase. Cancer Res. 1996a;56:4142–4145.
Mineishi S, Nakahara S, Takebe N, Banerjee D, Zhao SC, Bertino JR . Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene. Gene Therapy. 1997;4:570–576.
Tong Y, Liu-Chen X, Ericikan-Abali EA, et al. Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. J Biol Chem. 1998b;273:31209–31214.
Sauerbrey A, McPherson JP, Ahao S, Banerjee D, Bertino JR . Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. Hum Gene Ther. 1999;10:2495–2504.
Takebe N, Zhao SC, Ural AU, et al. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD 34+-enriched peripheral blood progenitor cells. Cancer Gene Ther. 2001;8:966–973.
Coutre LA, Mullen CA, Morgan RA . Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. Hum Gene Ther. 1994;5:667–677.
Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H . Review of a promising new agent — pemetrexed disodium. Cancer. 2003;97(Suppl):2056–2063.
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
Acknowledgements
This work was supported by grants P01 CA59350, RO1 CA-08010, and R01-CA 44355(FM).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Capiaux, G., Budak-Alpdogan, T., Alpdogan, O. et al. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Cancer Gene Ther 11, 767–773 (2004). https://doi.org/10.1038/sj.cgt.7700683
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700683
Keywords
This article is cited by
-
Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates
Gene Therapy (2016)
-
Efficient in vivo regulation of cytidine deaminase expression in the haematopoietic system using a doxycycline-inducible lentiviral vector system
Gene Therapy (2013)
-
Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection
Cancer Chemotherapy and Pharmacology (2006)